Invivyd expects to advance VBY329 toward IND readiness in 2H 2026 for development in pediatric RSV prophylaxis, a blockbuster pharmaceutical market in 2024, expected to grow to $3-$4 billion in annual ...

Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial (“BACKBEAT Trial”) by the end of Q3 2026Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking ...

“Our QUELIMMUNE net revenue in the first quarter was $495,000, a solid increase of 69% from the first quarter of last year,” said (Senior Vice President of Commercial & Business Operations Tim Varacek ...

PolyPid (NASDAQ:PYPD) held its first-quarter earnings conference call on Wednesday. Below is the complete transcript from the ...

I'd like to remind you that during this call, SuperCom management may be making forward-looking statements, including statements that address SuperCom's expectations for future performance or ...

Clinical results from the zanidatamab combination trial showed a 100% response rate in centrally confirmed HER2-positive/CD47 ...

Detailed price information for Alx Oncology Holdings Inc (ALXO-Q) from The Globe and Mail including charting and trades.

Detailed price information for Nexa Resources S.A. (NEXA-N) from The Globe and Mail including charting and trades.

Orchestra BioMed targeting enrollment completion of BACKBEAT Global Pivotal Trial ("BACKBEAT Trial") by the end of Q3 2026Medtronic (NYSE: MDT) and Orchestra BioMed intend to pursue late-breaking clin ...

Initiated NDA Submission to the FDA for D-PLEX₁₀₀ ; Completion Expected Imminently U.S. Commercial Partnership Discussions in Late ...

First Boric Acid Offtake Agreement -- 7,500 tons per year signed with a domestic and industrial boric acid end user, ...

Discover common accounting errors and learn how to detect and prevent them effectively. Ensure your financial statements are ...